Ultragenyx Pharmaceutical Inc. stocks have been trading up by 3.37 percent following upbeat sentiment around its latest clinical progress.
Click Here for a Millionaire's POV on Trading RARE
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
What Traders Need To Know
- Ultragenyx won accelerated FDA approval for Genglycos in GSDIa, secured a Priority Review Voucher, and set a $2.7M list price, with BofA lifting its target to $48 on strong commercial potential.
- Ninety-six-week Phase 3 data for Genglycos showed a 61% drop in daily cornstarch use with stable glycemic control and a manageable safety profile, supporting durable real-world benefit.
- Ahead of the Aspire data, major banks raised Ultragenyx price targets, with Morgan Stanley going to $74 and highlighting GTX-102 as a key near-term catalyst.
- The GTX-102 Aspire trial in Angelman syndrome failed all primary and secondary endpoints, driving sharp target cuts from Citi and H.C. Wainwright even as both kept Buy ratings.
- Following Aspire’s failure, shares plunged 44.6% intraday to $14.70, while Wedbush and William Blair turned more cautious, tightening the risk–reward for short-term traders.
Weekly Update Aug 31 – Sep 04, 2026: On Friday, September 04, 2026 Ultragenyx Pharmaceutical Inc. stock [NASDAQ: RARE] is trending up by 3.37%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Healthcare industry expert:
Analyst sentiment – neutral
Ultragenyx (RARE) remains a high‑risk, late‑stage rare‑disease platform with strong top‑line momentum but structurally weak fundamentals. Revenue of ~$673M with 21% 3‑yr CAGR and 87.8% gross margin confirms robust pricing power, yet EBIT margin of -79% and ROA of roughly -46% highlight an unprofitable model highly dependent on capital markets. Negative equity, large accumulated deficits, and Q2’26 operating cash burn of ~$97M leave a finite runway despite ~$292M in cash and investments.
Technically, the stock has shifted from a stable mid‑20s range (closes at 25.31 and 25.51 on 8/31–9/1) to a sharp breakdown into the mid‑teens following the GTX‑102 failure (15.16–14.90 closes on 9/2–9/3) with modest stabilization at 15.36. Intraday 5‑minute tape shows heavy volume on the gap‑down and lighter, two‑way trade afterward, indicating capitulation followed by bottom‑fishing. The dominant trend is now down; $15 is pivotal support, with $18 as a tactical short‑term resistance and re‑risk level.
More Breaking News
- SDEV Stock Jumps As Traders Pile Into Volatile Move
- FRMI Stock Slides As Weak Financials Test Trader Patience
- CTVA Stock Drops As PFAS Settlement Weighs On Sentiment
- FROG Stock Climbs As JFrog Doubles Down On AI Security
Fundamentally, the FDA’s accelerated approval of Genglycos and strong 96‑week data support a durable, high‑value rare‑disease franchise, but the GTX‑102 Phase 3 failure removes a major upside driver and justifies multiple compression versus high‑growth biotech benchmarks. Street targets have reset toward the mid‑20s to low‑30s, still above current price yet below prior $50–80 bull cases. Relative to healthcare and biotech indices, risk remains elevated; risk/reward is now balanced. Optimal entry is near $14–15 with $13 support, targeting a 6–12‑month rebound toward $24–26.
Quick Financial Overview
Ultragenyx Pharmaceutical Inc. (RARE) is trading through a classic biotech whipsaw. In the weekly data, RARE sat around $25.31, then $25.51, before collapsing to the mid-teens, with lows near $14.90 and only a slight bounce to about $15.36. That slide lines up with the GTX-102 Aspire failure, which triggered a 44.6% intraday drop to $14.70 in one session, telling you just how much hope was priced into that program.
The intraday 5‑minute tape around the mid-teens shows heavy churn between roughly $15.20 and $15.80, with repeated pushes toward $16 that fade. Price is now trapped in a tight range, signaling short-term equilibrium after forced selling. For active traders, that $15 zone is the new battleground: sustained trade above the intraday highs near $16 would signal short-covering, while a break back under $15 would warn that liquidation is not done.
On the fundamentals, Ultragenyx posted about $673M in revenue with strong 87.8% gross margin, but very negative profitability metrics, including an EBIT margin near -79%. The latest quarterly report shows $214M in revenue and a net loss of $92M, with operating cash flow at about -$97M. Cash and equivalents of roughly $292M (including short-term investments) and a current ratio of 1.7 give RARE some runway, but the negative book value and high cash burn keep the story firmly in high-risk biotech territory.
Conclusion
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.